The Facilities and Lab Operations Sr. Associate will ensure the smooth and efficient operation of SAB’s facilities. The Facilities Associate is responsible for supporting the Facilities Manager in the daily operation, maintenance, and continuous improvement of laboratory, office, warehouse, and facility systems. The incumbent will thrive in a fast-paced environment and demonstrate a strong commitment to maintaining a safe, clean, and compliant workplace.
The Facilities Associate plays a critical role in maintaining laboratory functionality by supporting facility infrastructure, responding to maintenance needs, coordinating service activities, and ensuring compliance with company policies, safety regulations, and applicable GMP requirements.
This position does not have supervisory responsibilities.
While performing the duties of this job, the employee is regularly required to walk, stand, and sit. The employee must regularly lift and/or move up to 25-30 pounds. May occasionally lift and/or move up to 50 pounds with assistance. Specific vision abilities required by this job include close vision, peripheral vision, and the ability to adjust focus.
Biotech/Pharma-type laboratory working environment and conditions.
The employer will make reasonable accommodations in compliance with the Americans with Disabilities Act of 1990.
This job description will be reviewed periodically as duties and responsibilities change with business necessity. Primary and additional duties and responsibilities are subject to modification.
SAB BIO is an Equal Opportunity Employer and prohibits discrimination and harassment of any kind. SAB BIO is committed to the principle of equal employment opportunity for all employees and does not discriminate based on race, religion, color, sex, gender identify, sexual orientation, age, non-disqualifying physical or mental disability, national origin, veteran status or any other legally protected status. EOE/AA/Vets

At SAB BIO, our mission is to dramatically redefine what it means to be diagnosed with type 1 diabetes (T1D) by developing a medicine to change the course of disease, not just treat symptoms.
SAB BIO is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The Company was founded in 2014 and traded on Nasdaq (SABS) since 2021.
Using advanced genetic engineering and antibody science, SAB BIO developed a proprietary technology which holds the potential to generate additional novel therapeutic candidates utilizing the human immune response, without the need for human donors or convalescent plasma.
To date, SAB BIO has conducted seven clinical trials that have dosed 700 individuals across multiple therapeutic areas. The safety and immunogenicity database for these trials shows zero patients with serum sickness or neutralizing anti-drug antibodies, which suggests an improved safety profile over other therapies.
SAB BIO’s lead product candidate, SAB-142, targets autoimmune T1D with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients.